Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth

Cell Metabolism

Volumn 25, Issue 2, 2017, Pages 358-373

  Xia, Siyuan ^a   Lin, Ruiting ^a   Jin, Lingtao ^a   Zhao, Liang ^a   Kang, Hee Bum ^a   Pan, Yaozhu ^a   Liu, Shuangping ^a   Qian, Guoqing ^a   Qian, Zhiyu ^a   Konstantakou, Evmorfia ^a   Zhang, Baotong ^a   Dong, Jin Tang ^a   Chung, Young Rock ^b   Abdel Wahab, Omar ^b   Merghoub, Taha ^b   Zhou, Lu ^c   Kudchadkar, Ragini R ^a   Lawson, David H ^a   Khoury, Hanna J ^a   Khuri, Fadlo R ^a   Boise, Lawrence H ^a   Lonial, Sagar ^a   Lee, Benjamin H ^d   Pollack, Brian P ^a,e   Arbiser, Jack L ^a,e   Fan, Jun ^a   Lei, Qun Ying ^c   Chen, Jing ^a   more..

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c FUDAN UNIVERSITY   (China)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^e ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

acetoacetate; BRAF V600E; cancer metabolism; cancer prevention; cancer risk; cancer therapy; dehydroacetic acid; dietary fat; ketogenesis; precision diet

Indexed keywords

3 HYDROXYBUTYRIC ACID; ACETOACETIC ACID; ANTILIPEMIC AGENT; B RAF KINASE; CHOLESTEROL; DEHYDROACETIC ACID; FENOFIBRATE; FLUINDOSTATIN; GLUCOSE; KETONE BODY; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NICOTINIC ACID; TRIACYLGLYCEROL; ACETOACETIC ACID DERIVATIVE; FAT INTAKE; PYRONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER PREVENTION; CONTROLLED STUDY; FAT INTAKE; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; KETOGENESIS; KETOGENIC DIET; LIPID DIET; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN BINDING; TUMOR GROWTH; ADVERSE EFFECTS; ANIMAL; BLOOD; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENETICS; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; MUTATION; NUDE MOUSE; PATHOLOGY;

3-HYDROXYBUTYRIC ACID; ACETOACETATES; ANIMALS; CELL PROLIFERATION; DIETARY FATS; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; INJECTIONS, INTRAPERITONEAL; KETONE BODIES; MELANOMA; MICE; MICE, NUDE; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; PYRONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85009468530     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2016.12.010     Document Type: Article

References (41)

1. Amjadi, F., Javanmard, S.H., Zarkesh-Esfahani, H., Khazaei, M., Narimani, M., Leptin promotes melanoma tumor growth in mice related to increasing circulating endothelial progenitor cells numbers and plasma NO production. J. Exp. Clin. Cancer Res., 30, 2011, 21.
2. Antoniadis, A.G., Petridou, E.T., Antonopoulos, C.N., Dessypris, N., Panagopoulou, P., Chamberland, J.P., Adami, H.O., Gogas, H., Mantzoros, C.S., Insulin resistance in relation to melanoma risk. Melanoma Res. 21 (2011), 541–546.
3. Arcaini, L., Zibellini, S., Boveri, E., Riboni, R., Rattotti, S., Varettoni, M., Guerrera, M.L., Lucioni, M., Tenore, A., Merli, M., et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood 119 (2012), 188–191.
4. Avis, H.J., Vissers, M.N., Stein, E.A., Wijburg, F.A., Trip, M.D., Kastelein, J.J., Hutten, B.A., A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 27 (2007), 1803–1810.
5. Balasse, E.O., Féry, F., Ketone body production and disposal: effects of fasting, diabetes, and exercise. Diabetes Metab. Rev. 5 (1989), 247–270.
6. Benlloch, S., Payá, A., Alenda, C., Bessa, X., Andreu, M., Jover, R., Castells, A., Llor, X., Aranda, F.I., Massutí, B., Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology. J. Mol. Diagn. 8 (2006), 540–543.
7. Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., Hirth, P., Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat. Rev. Drug Discov. 11 (2012), 873–886.
8. Brandon, E.L., Gu, J.W., Cantwell, L., He, Z., Wallace, G., Hall, J.E., Obesity promotes melanoma tumor growth: role of leptin. Cancer Biol. Ther. 8 (2009), 1871–1879.
9. Brummer, T., Martin, P., Herzog, S., Misawa, Y., Daly, R.J., Reth, M., Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein. Oncogene 25 (2006), 6262–6276.
10. Chapman, M.A., Lawrence, M.S., Keats, J.J., Cibulskis, K., Sougnez, C., Schinzel, A.C., Harview, C.L., Brunet, J.P., Ahmann, G.J., Adli, M., et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471 (2011), 467–472.
11. Chen, J., Chi, M., Chen, C., Zhang, X.D., Obesity and melanoma: exploring molecular links. J. Cell. Biochem. 114 (2013), 1955–1961.
12. Cotter, D.G., Schugar, R.C., Crawford, P.A., Ketone body metabolism and cardiovascular disease. Am. J. Physiol. Heart Circ. Physiol. 304 (2013), H1060–H1076.
13. Dennis, L.K., Lowe, J.B., Lynch, C.F., Alavanja, M.C., Cutaneous melanoma and obesity in the Agricultural Health Study. Ann. Epidemiol. 18 (2008), 214–221.
14. Fu, Z., Runquist, J.A., Montgomery, C., Miziorko, H.M., Kim, J.J., Functional insights into human HMG-CoA lyase from structures of Acyl-CoA-containing ternary complexes. J. Biol. Chem. 285 (2010), 26341–26349.
15. Gibney, G.T., Messina, J.L., Fedorenko, I.V., Sondak, V.K., Smalley, K.S., Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma. Nat. Rev. Clin. Oncol. 10 (2013), 390–399.
16. Greenwald, P., Clifford, C.K., Milner, J.A., Diet and cancer prevention. Eur. J. Cancer 37 (2001), 948–965.
17. Hay, R.W., Bond, M.A., Kinetics of the decarboxylation of acetoacetic acid. Aust. J. Chem. 20 (1967), 1823–1828.
18. Hitosugi, T., Zhou, L., Elf, S., Fan, J., Kang, H.B., Seo, J.H., Shan, C., Dai, Q., Zhang, L., Xie, J., et al. Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell 22 (2012), 585–600.
19. Iles, M.M., Law, M.H., Stacey, S.N., Han, J., Fang, S., Pfeiffer, R., Harland, M., Macgregor, S., Taylor, J.C., Aben, K.K., et al. A variant in FTO shows association with melanoma risk not due to BMI. Nat. Genet. 45 (2013), 428–432.
20. Jacobson, T.A., Chin, M.M., Fromell, G.J., Jokubaitis, L.A., Amorosa, L.F., Fluvastatin with and without niacin for hypercholesterolemia. Am. J. Cardiol. 74 (1994), 149–154.
21. Johnson, D.B., Sosman, J.A., Update on the targeted therapy of melanoma. Curr. Treat. Options Oncol. 14 (2013), 280–292.
22. Kang, H.B., Fan, J., Lin, R., Elf, S., Ji, Q., Zhao, L., Jin, L., Seo, J.H., Shan, C., Arbiser, J.L., et al. Metabolic rewiring by oncogenic BRAF V600E links ketogenesis pathway to BRAF-MEK1 signaling. Mol. Cell 59 (2015), 345–358.
23. Kennedy, A.R., Pissios, P., Otu, H., Roberson, R., Xue, B., Asakura, K., Furukawa, N., Marino, F.E., Liu, F.F., Kahn, B.B., et al. A high-fat, ketogenic diet induces a unique metabolic state in mice. Am. J. Physiol. Endocrinol. Metab. 292 (2007), E1724–E1739.
24. Kim, J.W., Dang, C.V., Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 66 (2006), 8927–8930.
25. Kirkpatrick, C.S., White, E., Lee, J.A., Case-control study of malignant melanoma in Washington State. II. Diet, alcohol, and obesity. Am. J. Epidemiol. 139 (1994), 869–880.
26. Kroemer, G., Pouyssegur, J., Tumor cell metabolism: cancer's Achilles’ heel. Cancer Cell 13 (2008), 472–482.
27. Martinez Molina, D., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E.A., Dan, C., Sreekumar, L., Cao, Y., Nordlund, P., Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341 (2013), 84–87.
28. McPherson, P.A., McEneny, J., The biochemistry of ketogenesis and its role in weight management, neurological disease and oxidative stress. J. Physiol. Biochem. 68 (2012), 141–151.
29. Menao, S., López-Viñas, E., Mir, C., Puisac, B., Gratacós, E., Arnedo, M., Carrasco, P., Moreno, S., Ramos, M., Gil, M.C., et al. Ten novel HMGCL mutations in 24 patients of different origin with 3-hydroxy-3-methyl-glutaric aciduria. Hum. Mutat. 30 (2009), E520–E529.
30. Miller, A.B., Diet and cancer. A review. Acta Oncol. 29 (1990), 87–95.
31. Morris, A.A., Cerebral ketone body metabolism. J. Inherit. Metab. Dis. 28 (2005), 109–121.
32. Oh, S.W., Yoon, Y.S., Shin, S.A., Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J. Clin. Oncol. 23 (2005), 4742–4754.
33. Pandey, V., Vijayakumar, M.V., Ajay, A.K., Malvi, P., Bhat, M.K., Diet-induced obesity increases melanoma progression: involvement of Cav-1 and FASN. Int. J. Cancer 130 (2012), 497–508.
34. Sebolt-Leopold, J.S., Herrera, R., Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 4 (2004), 937–947.
35. Sergentanis, T.N., Antoniadis, A.G., Gogas, H.J., Antonopoulos, C.N., Adami, H.O., Ekbom, A., Petridou, E.T., Obesity and risk of malignant melanoma: a meta-analysis of cohort and case-control studies. Eur. J. Cancer 49 (2013), 642–657.
36. Shors, A.R., Solomon, C., McTiernan, A., White, E., Melanoma risk in relation to height, weight, and exercise (United States). Cancer Causes Control 12 (2001), 599–606.
37. Skaff, D.A., Ramyar, K.X., McWhorter, W.J., Barta, M.L., Geisbrecht, B.V., Miziorko, H.M., Biochemical and structural basis for inhibition of Enterococcus faecalis hydroxymethylglutaryl-CoA synthase, mvaS, by hymeglusin. Biochemistry 51 (2012), 4713–4722.
38. Stedman, R.L., Engel, S.L., Bilse, I.M., In vitro antimicrobial activity of a dehydroacetic acid and p-chlor-m-xylenol combination. J. Am. Pharm. Assoc. Am. Pharm. Assoc. 43 (1954), 622–624.
39. Superko, H.R., A review of combined hyperlipidaemia and its treatment with fenofibrate. J. Int. Med. Res. 17 (1989), 99–112.
40. Tennant, D.A., Durán, R.V., Gottlieb, E., Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 10 (2010), 267–277.
41. Tomoda, H., Ohbayashi, N., Morikawa, Y., Kumagai, H., Omura, S., Binding site for fungal beta-lactone hymeglusin on cytosolic 3-hydroxy-3-methylglutaryl coenzyme A synthase. Biochim. Biophys. Acta 1636 (2004), 22–28.